

Servier accelerates access to breakthrough innovation with the launch of Servier Ventures, its strategic corporate venture fund

- Servier Ventures to invest €200 million in biotech and technological companies advancing cutting-edge therapeutic approaches to support innovation primarily across Europe.
- The creation of this fully owned fund supports Servier's strategy to strengthen early access to innovation in the Group's key therapeutic areas of oncology and neurology.

Suresnes (France), January 8, 2026 – Servier, an independent international pharmaceutical company governed by a Foundation, announces the creation of Servier Ventures, a fully owned corporate venture fund. The fund is committed to investing an initial amount of €200 million in innovative biotech and technological companies.

The primary goal is to invest in biotech companies shaping the future of oncology and neurology, expanding Servier's reach across the global innovation ecosystem to advance science and unlock tomorrow's breakthrough therapies for the benefit of patients.

Building on Servier's existing innovation efforts and its investments as a limited partner in venture capital, Servier Ventures will further reinforce the Group's position within the innovation ecosystem.

Olivier Laureau, President of Servier, commented: “*The creation of Servier Ventures is fully aligned with our mission to drive therapeutic progress and address unmet patient needs. Today, we invest a significant portion of our sales to develop our R&D pipeline. This commitment includes supporting innovative companies seeking to deliver transformative scientific solutions for patients.*”

Investments will be made through minority stakes in innovative biotech and technological companies operating within Servier's therapeutic fields of oncology and neurology. Initially, this fund will primarily invest in Europe with the possibility of expanding to other regions in the future.

Alexis Vandier, newly appointed Global Head of Servier Ventures, added: “*In line with the Group's strategy, Servier Ventures will finance and support emerging biotech companies and, if needed, provide them access to Servier's scientific expertise and capabilities, to boost their potential and foster the creation of innovative new medicines. The creation of the fund will strengthen Servier's positioning as a partner of choice for promising companies seeking to take a strategic step forward, aligned with our focus toward innovation for the benefit of patients.*”

Media contact

laura.visserias.part@servier.com

About Servier

Servier is an independent international pharmaceutical company governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.

Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development.

As a world leader in hypertension and venous diseases and a major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective.

Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of rare neurological diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine.

To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice.

Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion.

Plus d'informations sur le nouveau site du Groupe : servier.com

Suivez-nous sur les réseaux sociaux : [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

